Characteristics of 222 Patients Treated with RGS Between 2014 and 2020 at 2 Centers*
| Parameter | Early SPECT (≤4 h after injection; n = 44) | Late SPECT (≥15 h after injection; n = 178) | P |
|---|---|---|---|
| Year of initial RP | 2010 (2005–2013) | 2014 (2010–2016) | <0.001 |
| PSA at RP (ng/mL) | 10 (6–16) | 9 (6–15) | 0.8 |
| Lymph node yield at RP | 13 (8–20) | 13 (8–20) | 0.6 |
| Positive lymph nodes at RP | 0.6 | ||
| 0 | 32 (73) | 115 (65) | |
| 1 | 3 (6.8) | 19 (11) | |
| 2 | 3 (6.8) | 9 (5.1) | |
| ≥3 | 2 (4.5) | 5 (2.8) | |
| Unknown | 4 (9.1) | 30 (17) | |
| Surgical margin status | 0.05 | ||
| R0 | 29 (66) | 130 (73) | |
| R1 | 9 (20) | 41 (23) | |
| RX/NA | 6 (14) | 7 (3.9) | |
| RT after RP | 0.1 | ||
| No RT | 15 (34) | 59 (33) | |
| RT after RP | 28 (64) | 119 (67) | |
| NA | 1 (2.3) | 0 (0) | |
| Time from RP to SPECT (mo) | 70 (22–128) | 46 (22–88) | 0.2 |
| Age at PSMA RGS (y) | 72 (65–75) | 66 (61–70) | <0.001 |
| PSA before SPECT (ng/mL) | 1.4 (0.7–3.0) | 1.0 (0.5–2.0) | 0.09 |
* Patients received [99mTc]Tc-PSMA-I&S SPECT/CT before surgery and presented with BCR after RP with histopathology-confirmed positive lesions at PSMA PET/CT.
NA = not assigned; RT = radiotherapy.
Qualitative data are number and percentage; continuous data are median and IQR.